secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2023-04-24T23:59:59+00:00
Accession:  0000950170-23-014115
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARCA biopharma reports Q1 net loss of $1.3M; strategic review ongoing
---------------------------------------------------------------------

- Net loss of $1.3M ($0.09 per share) vs $3.3M ($0.23) in Q1 2022; improvement due to lower R&D costs.
- Cash and equivalents $40.9M as of March 31, 2023, expected to fund operations through mid-2024.
- Strategic review process continues with Ladenburg Thalmann; evaluating merger, asset sale, or other options.
- R&D expenses fell to $0.4M from $2.2M YoY after enrollment completion in rNAPc2 Phase 2b trial.
- G&A expenses rose to $1.4M from $1.1M, including $159K severance for former General Counsel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000095017023014115/0000950170-23-014115-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000095017023014115/abio-20230424.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-014115

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer